Surface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL
Authors:
- Lucien CourtoisLCLucien Courtois
- Antoine PintonAPAntoine Pinton
- Aurélie Cabannes-HamyACAurélie Cabannes-Hamy
- Mathieu SimoninMSMathieu Simonin
- Guillaume P. AndrieuGAGuillaume P. Andrieu
- Mélodie QueriMQMélodie Queri
- Charlotte SmithCSCharlotte Smith
- Guillaume CharbonnierGCGuillaume Charbonnier
- Marie-Emilie DourtheMDMarie-Emilie Dourthe
- Marianne CourgeonMCMarianne Courgeon
- 12 June 2025
- journal article
- Published by American Society of Hematology in Blood
- Vol. 145 (24) , 2903-2913
Abstract
Refractory and/or relapsing T-cell acute lymphoblastic leukemia (T-ALL) remains a major therapeutic challenge. The pre–T-cell receptor (TCR) pathway has recently emerged as a therapeutic target via LCK inhibition in this context. However, there is a need for simple and quickly assessable biomarkers to predict sensitivity to LCK inhibitors. Moreover, targeting LCK alone by tyrosine kinase inhibitors, such as dasatinib, often results in transient clinical responses, emphasizing the need for efficient combination strategies. Here, we assessed pre-TCR α chain (pTα) surface expression by flow cytometry in a unique series of 50 adult T-ALL patient-derived xenografts (PDXs). We show that cases displaying a cortical phenotype often express high levels of surface pTα (pre-TCR+ T-ALL) and that the latter associates with LCK activation. Furthermore, we show that ectopic interleukin-7 receptor (IL-7R) expression can rescue pre-TCR+ T-ALL from dasatinib cytotoxicity (5 PDXs). We tested whether coinhibition of pre-TCR and IL-7R signaling pathways could be synergetic in pre-TCR+ IL-7R+ T-ALL (11 PDXs). Combination of JAK inhibitors, ruxolitinib or tofacitinib, with dasatinib elicited strong and specific synergy in IL-7R+ pre-TCR+ T-ALL in vitro, including in the relapse setting (4 of 28 patient-derived primary samples). Using 3 adult-PDX models, we show that in vivo treatment with this combination significantly delayed leukemic progression and prolonged survival compared with either monotherapy. This preclinical study thus proposes the use of pTα as a biomarker of LCK-inhibitor sensitivity in T-ALL, and suggests that dual targeting of IL-7R and pre-TCR signaling pathways may be a relevant therapeutic strategy in a substantial proportion of adult T-ALL.Keywords
This publication has 33 references indexed in Scilit:
- The genomic basis of childhood T-lineage acute lymphoblastic leukaemiaNature, 2024
- Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategiesNature Communications, 2022
- New insights into TCR β-selectionTrends in Immunology, 2021
- Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemiaNature Cancer, 2021
- Distinct and temporary-restricted epigenetic mechanisms regulate human αβ and γδ T cell developmentNature Immunology, 2020
- Flip the coin: IL-7 and IL-7R in health and diseaseNature Immunology, 2019
- In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALLBlood Cancer Journal, 2017
- Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL studyBlood Cancer Journal, 2016
- Transcription factors and target genes of pre-TCR signalingCellular and Molecular Life Sciences, 2015
- Differential IL-7 responses in developing human thymocytesHuman Immunology, 2010